What are other genetic mutations associated with aHUS?

This medication helps to block the decrease in red blood cells and can improve the symptoms of anemia (such as tiredness, shortness of breath) and decrease the ... Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... Mar 15, 2025 ... The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to ... Your browsing activity is empty. Activity recording is turned off. Turn recording back on. See more... Follow NCBI. Connect with NLM. National Library of ... Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. Jun 10, 2024 ... Soliris (eculizumab) is a monoclonal antibody that works to reduce the destruction of red blood cells in people with paroxysmal nocturnal ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. ... Eculizumab has a long duration of ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... Mar 6, 2012 ... For these very small children, eculizumab should be considered first. In larger children who can be treated with plasma exchange, treatment with ...